REPL earnings analysis
What we found in REPL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Replimune’s quarterly loss and EPS improved versus both the preceding quarter and the prior-year period, but the filing extract does not provide total revenue, margins, or segment results and the company has not generated product-sales revenue to date. FDA approval of TUDRIQEV is a significant catalyst, while the accelerated-approval requirement for confirmatory clinical benefit and the need to build commercial capabilities create substantial execution risk. Liquidity was strengthened by $141.0 million of August offering proceeds, with management expecting funding for greater than twelve months, but additional financing is still expected to be required.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net loss narrowed year over year
- Net loss was $69.8 million for the three months ended June 30, 2026, versus $86.7 million in the prior-year period, an improvement of $16.9 million or approximately 19.5%.
- EPS improved sequentially
- Diluted EPS was -$0.76, improving from -$0.90 in the preceding quarter and -$0.82 in the prior-year quarter; however, the reported EPS was below the $0.70 consensus estimate in the supplied earnings data.
- TUDRIQEV received FDA approval
- The FDA approved TUDRIQEV in August 2026 in combination with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1 regimen, enabling preparation for a U.S. commercial launch.
- Liquidity extended beyond twelve months
- Cash, cash equivalents and short-term investments totaled $195.3 million at June 30, 2026. Management expects the additional $141.0 million of net proceeds from the August 2026 common-stock offering, together with existing liquidity, to fund operations for greater than twelve months.
- SEC investigation closed favorably
- The SEC concluded its investigation on June 24, 2026 and stated that it was not recommending an enforcement action against Replimune.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, and reported no material changes in internal control over financial reporting during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Accelerated approval remains contingent
- TUDRIQEV was approved under accelerated approval based on overall response rate and duration of response, and continued approval depends on verification of clinical benefit in confirmatory studies including IGNYTE-3. The company previously received two FDA complete response letters, with the second issued on April 10, 2026, so failure of the required studies could lead to withdrawal of approval.
- No product revenue and ongoing funding need
- The company reported no revenue from product sales to date, a $69.8 million net loss for the latest quarter and an accumulated deficit of $1,332.3 million at June 30, 2026. Management states that additional financing will be required, creating dilution and liquidity risk if future capital is unavailable on acceptable terms.
- Additional securities litigation filed
- A new securities class action was filed on August 6, 2026, alleging substantially the same facts as the existing litigation related to the RP1 BLA. The company and other defendants’ response to the earlier second amended complaint was due August 17, 2026, increasing legal and reputational exposure following the two FDA CRLs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.76
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided in the filing extract. Management stated that $141.0 million of net August 2026 offering proceeds, together with cash, cash equivalents and short-term investments at June 30, 2026, is expected to fund operations for greater than twelve months, including TUDRIQEV commercialization and working capital.
The filing reads about the same as the one before it.
What came before.
- 10-K · June 29, 2026
- Replimune Group, Inc.'s 2026 10-K reveals a challenging year marked by a continuing net loss of $313.9 million, an operational cash burn that necessitates urgent funding, and no revenue generated to date as the company…
- 10-Q · February 8, 2024
- Replimune reported a Q3 net loss of $51.1 million (EPS -$0.77) versus a loss of $39.7 million (EPS -$0.69) in the prior-year quarter, driven by higher R&D and SG&A spend. Cash and short-term investments totaled $97,672…
- 10-Q · August 3, 2023
- Replimune reported a Q1 net loss of $49.6M ($0.75 per share), modestly better than the prior-year quarter loss per share of $0.78. Operating expenses rose meaningfully as R&D increased to $40.4M and SG&A to $15.2M,…
- 10-Q · August 4, 2022
- Replimune reported a larger net loss for the quarter ended June 30, 2022: a net loss of $42,253 (three months) vs $27,311 in the prior-year quarter, and loss per share widened to $(0.78) from $(0.53). Cash + short-term…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing REPL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever